WI-211094
/ WhanIn
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
October 10, 2022
Characterization of a novel small-molecule LRRK2 inhibitor WI-211094 as a potential therapeutic agent for Parkinson's disease
(Neuroscience 2022)
- "In mice, WI-211094 was well tolerated up to 1000 mg/kg once daily for 2 weeks without histopathological alterations in tissues, especially lung adverse effects. Taken together, we suggest that WI-211094, a novel, advanced, and generally safe LRRK2 inhibitor, might be a potential therapeutic candidate for both iPD patients and familial PD patients with LRRK2 mutation."
CNS Disorders • Parkinson's Disease • TNFA
1 to 1
Of
1
Go to page
1